Shield Therapeutics (STU:1JS) Other Operating Expense: €0.93 Mil (TTM As of Dec. 2025)


What is Shield Therapeutics Other Operating Expense?

Shield Therapeutics STU:1JS Other Operating Expense is €0.93 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Shield Therapeutics's Other Operating Expense for the six months ended in Dec. 2025 was €0.32 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €0.93 Mil.

Shield Therapeutics's quarterly Other Operating Expense increased from Dec. 2024 (€0.58 Mil) to Jun. 2025 (€0.62 Mil) but then declined from Jun. 2025 (€0.62 Mil) to Dec. 2025 (€0.32 Mil).

Shield Therapeutics's annual Other Operating Expense increased from Dec. 2023 (€-3.06 Mil) to Dec. 2024 (€1.27 Mil) but then declined from Dec. 2024 (€1.27 Mil) to Dec. 2025 (€0.92 Mil).

Shield Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Other Operating Expense Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.50 1.90 -3.06 1.27 0.92

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.67 0.58 0.62 0.32

Shield Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €0.93 Mil mean?
Shield Therapeutics (STU:1JS) has a Other Operating Expense of €0.93 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Other Operating Expense too high?
Shield Therapeutics' current Other Operating Expense is €0.93 Mil.
How does Shield Therapeutics' Other Operating Expense compare to ZTS and UTHR?
Shield Therapeutics' Other Operating Expense of €0.93 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Other Operating Expense is €0.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Other Operating Expense is €0.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Other Operating Expense is €0.93 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.